You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物(09926.HK):依沃西聯合化療對比替雷利珠單抗聯合化療一線治療SQ-NSCLC的AK112-306/HARMONI-6III期臨牀達到PFS顯著陽性結果,具有統計學顯著意義和重大臨牀獲益

格隆匯4月23日丨康方生物(09926.HK)發佈公告,全球首創雙特異性抗體新藥依達方®(依沃西,PD-1/VEGF)聯合化療對比替雷利珠單抗聯合化療一線治療晚期鱗狀非小細胞肺癌(sq-NSCLC)的III期頭對頭臨牀試驗(AK112-306/HARMONi-6),經獨立數據監察委員會(IDMC)評估,期中分析顯示強陽性結果:達到無進展生存期(PFS)的主要研究終點,具有統計學顯著意義和重大臨牀獲益。本研究詳細數據將在今年相關國際術會議上公佈。HARMONi-6(CTR20231272/NCT05840016)共入組532例受試者,中央型鱗癌佔比約爲63%,與真實世界患者分佈一致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account